Reduced levels of cholesterol, phospholipids, and fatty acids in cerebrospinal fluid of Alzheimer disease patients are not related to apolipoprotein E4

Alzheimer Disease and Associated Disorders

Volumn 12, Issue 3, 1998, Pages 198-203

  Mulder, M ^a   Ravid, R ^b   De Kloet, J E R ^c   Haasdijk, E D ^d   Julk, J ^e   Van Der Boom, J ^a   Havekes, L M ^d  

^a TNO   (Netherlands)

^b NETHERLANDS BRAIN BANK   (Netherlands)

^c NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

^d LEIDEN UNIVERSITY   (Netherlands)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer disease; Apolipoprotein E; Cerebrospinal fluid; Lipids

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E4; CHOLESTEROL; CHOLESTEROL ESTER; FATTY ACID; PHOSPHOLIPID;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENOTYPE; HOMEOSTASIS; HUMAN; HUMAN TISSUE; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; RISK FACTOR;

EID: 0032405857     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002093-199809000-00012     Document Type: Article

References (40)

1. Blennow K, Hesse C, Friedman P. Cerebrospinal fluid apolipoprotein E is reduced in Alzheimer's disease. NeuroReport 1994;5:2534-6.
2. Bligh EG, Dyer WJ. A rapid method for total lipid extraction and purification. CanJBiochem Physiol 1959;37:911-7.
3. Boyles JK, Pitas RE, Wilson E, Mahley RW, Taylor JM. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J Clin lin-est 1985;76:1501-13.
4. Brooksbank BWL, Martinez M. Lipid abnormalities in the brain in adult Down's syndrome and Alzheimer's disease. Mol Chem Neuropathol 1989;ll:157-85.
5. Bury J, Vercaemst R, Rosseneu M, et al. Apolipoprotein E quantified by enzyme-linked immunosorbent assay. Clin Chem 1986;32:265-70.
6. Carlsson J, Armstrong VW, Reiber H, Felgenhauer K, Seidel D. Clinical relevance of the quantification of apolipoprotein E in cerebrospinal fluid. Clin CliimAcIa 1991; 196:167-76.
7. Elshourbagy NA, Liao VS, Mahley RW, Taylor JM. Apolipoprotein E mRNA is abundant in the brain and adrenals, as well as in the liver, and is present in other peripheral tissues of rats and marmosets. Proc NatlAcadSciUSA 1985;82:203-7.
8. Giron NM, Criado MD, Lara A, Suarez MD. The short-term effect of dietary fats on the brain fatty acid composition in rats. Arch Physiol Biochem 1995;103:123-6.
9. Handelmann GE, Boyles JK, Weisgraber KH, Mahley RW, Pitas RE. Effects of apolipoprotein E, ß-very low density lipoproteins and cholesterol on the extension of neuntes by rabbit dorsal root ganglion neurons in vitro. J Lipid Res 1992;22:959-62.
10. Hardy JA, Wester P, Winblad B, Gezelius, Bring G, Eriksson A. The patients dying after long terminal phase have acidotic brains; implications for biochemical measurements on autopsy tissue. J Neural Trans 1985;61:253-64.
11. Havekes LM, de Knijff P, Beisiegel U, et al. A rapid method for apolipoprotein E phenotyping direct in serum. J Lipid Res 1987;28:455-63.
12. Helisalmi W, Linnaranta K, Lehtovirta M, et al. Apolipoprotein E polymorphism in patients with different neurodegenerative disorders. Neurosci Lett 1996;205:6-4.
13. Kotier HU, Hampel H, Möller. Total serum cholesterol and triglycérides in patients with Alzheimer's disease and healthy controls. Neurobiol Aging 1996;17(suppl 4S):S95.
14. Lehtimäki T, Pirttila T, Mehta PD, Wisniewski HM, Frey H, Nikkari T. Apolipoprotein E (apoE) polymorphism and its influence on apoE concentrations in the cerebrospinal fluid in Finnish patients with Alzheimer's disease. Hum Genet 1995;95:39-42.
15. Lowry OH, Rowebrough NJ, Farr AL, et al. Protein measurement with Folin phenol reagent. JBiol Chem 1951;193:265-75.
16. Mahley RW, Innerarity TL, Rail SC, Weisgraber KH, Taylor M. ApoE: cholesterol transport protein ith expanding role in cell biology. Science 1988;240:622-30.
17. Mashliah E, Mallory M, Ge N, Alford M, Veinbergs I, Roses AD. Neurodegeneration in central nervous system of apoE-deficient mice. Exp Neurology 1995;136:107-22.
18. McConnell H, Bianchine J. Composition of CSF. In: Chapman & Hall Medical, eds. Cerebrospinal fluid in neurology and psychiatry. London: Chapman & Hall, 1994a:57-l 10.
19. McConnell H, Bianchine J. Composition of CSF. In: Chapman & Hall Medical, eds. Cerebrospinal fluid in neurology and psychiatry. London: Chapman & Hall, 19946:122-4.
20. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDSADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939W.
21. Nathan BP, Bellosta S, Sanan DA, Weisgraber KH, Mahley RW, Pitas RE. Differential effects of apolipoprotein E3 and E4 on neuronal growth in vitro. Science 1994;264:850-2.
22. Nitsch RM, Blusztajn JK, Pitas AG, Sack BE, Wurtman PJ. Evidence for a membrane defect in Alzheimer's disease Proc NatlAcad Sei USA 1992;89:1671-5.
23. Okuizumi K, Onodera O, Tanaka H. ApoE-epsilon 4 and early-onset Alzheimer's disease. Nature Genet 1994;7:10-1.
24. Palowsky R, Barnes A, Salem N. Essential fatty acid metabolism in the feline: relationship between liver and brain production of long-chain polyunsaturated fatty acids. JLipid Res 1994;35:2032-40.
25. PirttilaT, Mehta PD, LehtimäkiT, et al. Relationship between apolipoprotein E4 allele and CSF amyloid ß-protein in Alzheimer's disease and controls. Neurosci Res Comm 1994;15:201-7.
26. Pitas RE, Boyles JK, Lee SH, Hui D, Weisgraber KH. Lipoproteins and their receptors in the central nervous system. JBiol Chem 1987;262:14352-60.
27. Poirier J. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trends Neurosci 1994;17:525-30.
28. Rail SC, Weisgraber KH, Innerarity TL, Mahley RV. Structural basis of receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects. Proc NallAcad Sei USA 1982;79:4695-700.
29. Ravid R, Van Zvieten EJ, Swaab DE Brain banking and the human hypothalamus-factors to match for, pitfalls and potentials. In: Swaab DF, Hofman MA, Mirmiran M, Ravid R, Van Leeuwcn FV, eds. Progress in brain research, vol 93. Amsterdam: Elsevier Science, 1992:83-95.
30. Rebeck G, Chung H, Mendez A, Growdon J, Hyman B. Form and function of apoE-containing lipoproteins in the CNS. Soc Neurosci Abstr 1995;21:1008.
31. Reimer P. Apolipoprotein E genotype on agarose gels. Clin Chem 1995; 41:1046-7.
32. Reisberg B, Ferris SH, Del Leon MJ, Crook T. The global deterioration scale for assessment of primary degenerative dementia. AmJPsychol 1982;139:1136-9.
33. Roheim PS, Carey M, Forte T, Vega GL. Apolipoproteins in human cerebrospinal fluid. Proc Nail Acad Sei USA 1979;76:46-9.
34. Roses AD. Perspective: on the metabolism of apolipoprotein E and the Alzheimer diseases. Exp Neural 1995;132:149-56.
35. Smit M, de KnijfFP, Rosseneu M, et al. Apolipoprotein E polymorphism in the Netherlands and its effect on plasma lipid and apolipoprotein levels. Hum Genet 1988;80:287-92.
36. Stokes CE, Hawthorne JN. Reduced phosphoinositide concentrations in anterior temporal cortex of Alzheimer-diseased brains. J Neurochem 1987;48:1018-21.
37. Swaab DF, Raadsheer FC, Endert E, Hofman MA, Kamphorst W, Ravid R. Increased cortisol levels in aging and Alzheimer's disease in postmortem cerebrospinal fluid. JNenroendocrinol 1994;6:681-7.
38. Swerdlow R, Marcus DL, Landman J, Kooby D, Frey VV, Freedman ML. Brain glucose metabolism in Alzheimer's disease. Am J Med Sei 1993;308:141-4.
39. Weisgraber KH. Apolipoprotein E distribution among human plasma lipoproteins: role of cysteine-arginine interchange at residue 112. J Lipid Res 1990;31:1503-11.
40. Wurtman RJ. Choline metabolism as a basis for the selective vulnerability of cholinergic neurons. Trends Neurosci 1992;15:117-22.